Acurx Pharmaceuticals (ACXP) to Release Quarterly Earnings on Tuesday

Acurx Pharmaceuticals (NASDAQ:ACXP) is expected to be announcing its earnings results before the market opens on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Acurx Pharmaceuticals Stock Performance

NASDAQ:ACXP opened at $0.46 on Monday. The firm has a market capitalization of $9.04 million, a PE ratio of -0.42 and a beta of -1.71. The stock has a 50-day simple moving average of $0.73 and a two-hundred day simple moving average of $1.29. Acurx Pharmaceuticals has a 52-week low of $0.43 and a 52-week high of $3.33.

Insider Transactions at Acurx Pharmaceuticals

In other news, CEO David P. Luci purchased 49,261 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was bought at an average cost of $1.01 per share, with a total value of $49,753.61. Following the completion of the purchase, the chief executive officer now owns 1,097,458 shares in the company, valued at approximately $1,108,432.58. This represents a 4.70 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 29.60% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Acurx Pharmaceuticals in a research note on Friday, January 10th.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.